IMV

Immunovaccine Inc. (TSX VENTURE:IMV), a clinical stage vaccine company, today
announced the signing of an Investigator-Initiated Study Agreement for the
ongoing evaluation of its DPX-0907 cancer vaccine at the Busto Arsizio Hospital
in Italy. Marco Bregni, M.D., head of the Oncology Unit of the Hospital of Busto
Arsizio, will serve as the principle investigator for the Phase I/II DPX-0907
clinical trial in patients with breast and ovarian cancer. Immunovaccine expects
the Phase I/II study to be initiated during the fourth quarter of 2013. 


DPX-0907, which incorporates Immunovaccine's DepoVax(TM) adjuvanting technology,
is a unique multi-targeted therapeutic vaccine designed to train the immune
system to recognize and attack cancer cells. A completed Phase I trial of the
vaccine therapy in breast, ovarian and prostate cancer patients showed DPX-0907
to be safe and well-tolerated while generating specific polyfunctional T cell
responses and triggering increases in antigen targeted CD8 T cells. These
positive results were published in the peer-reviewed Journal of Translational
Medicine in August 2012. 


"We are excited to have the opportunity to continue the clinical evaluation of
DPX-0907 and build on results from previous clinical research that showed this
unique immunotherapy is capable of generating polyfunctional T cell responses in
multiple tumor types," stated Dr. Bregni. "With this new study, we are eager to
examine the possibility of utilizing specific T cell responses generated by
DPX-0907 in an adoptive immunotherapy setting, and assess the potential of
vaccine combined with lymphoablative therapy and T cell reinfusion in inducing
immune response in patients with different tumor types."


"The promising results achieved to date with our DPX-0907 program, particularly
those related to safety and immune response, have positioned us to confidently
advance this program to the next phase of clinical development," said John
Trizzino, chief executive officer of Immunovaccine. "We are pleased to be
collaborating with Dr. Bregni and the team at Busto Arsizio Hospital on this
important study and look forward to generating additional data that will inform
our continued work with this exciting cancer vaccine program." 


About DPX-0907 

DPX-0907 combines seven tumor associated antigens (TAAs) with Immunovaccine's
novel DepoVax adjuvanting delivery platform, allowing for the creation of a
depot effect upon vaccination that presents the antigens and adjuvant to the
immune system for a prolonged period of time. Treatment with DPX-0907 is
designed to train the body's T cells, sophisticated white blood cells that play
a key role in fighting cancer, to recognize the antigens incorporated into the
vaccine. In doing so, the T cells become programmed to specifically target and
attack cancer cells, while leaving normal healthy cells unharmed. By
incorporating multiple target antigens, DPX-0907 attempts to attack cancer cells
through multiple avenues and potentially minimize the cancer cells' demonstrated
ability to edit and escape the impact of individual antigens. 


About DepoVax 

DepoVax(TM) is a patented formulation that provides controlled and prolonged
exposure of antigens plus adjuvant to the immune system, resulting in a strong,
specific and sustained immune response with the capability for single-dose
effectiveness. The DepoVax platform possesses impressive flexibility, allowing
it to work with a broad range of target antigens in various therapeutic
applications. The technology is also commercially scalable, with potential for
years of stability and ease of use in the clinic.


About Immunovaccine 

Immunovaccine Inc. applies its novel adjuvanting platform to the development of
vaccines for cancer therapy, infectious diseases and animal health. The
Company's DepoVax(TM) platform is a patented formulation that provides
controlled and prolonged exposure of antigens plus adjuvant to the immune
system. Immunovaccine has advanced two DepoVax-based cancer vaccines into Phase
I human clinical trials. The Company is also advancing a broad infectious
disease pipeline including vaccines in such indications as malaria, respiratory
syncytial virus (RSV) and anthrax. In addition to the Company's human health
vaccine strategy, it continues to capture value from animal health vaccine
applications. Immunovaccine has key partnerships in the animal health sector
including an agreement with Pfizer Animal Health. Connect at www.imvaccine.com.


This press release contains forward-looking information under applicable
securities law. All information that addresses activities or developments that
we expect to occur in the future is forward-looking information. Forward-looking
statements are based on the estimates and opinions of management on the date the
statements are made. However, they should not be regarded as a representation
that any of the plans will be achieved. Actual results may differ materially
from those set forth in this press release due to risks affecting the company,
including access to capital, the successful completion of clinical trials and
receipt of all regulatory approvals. Immunovaccine Inc. assumes no
responsibility to update forward-looking statements in this press release.


FOR FURTHER INFORMATION PLEASE CONTACT: 
Immunovaccine, Inc.
Dr. Marc Mansour
Chief Science Officer
(902) 492-1819
mmansour@imvaccine.com
www.imvaccine.com


Vida Communication (media)
Tim Brons
(415) 675-7402
tbrons@vidacommunication.com


Vida Communication (investors)
Stephanie Diaz
(415) 675-7401
sdiaz@vidacommunication.com


Brisco Capital Partners (Canadian investors)
Scott Koyich
(403) 262-9888
skoyich@briscocapital.com

(TSXV:IMV)
Historical Stock Chart
From Jun 2024 to Jul 2024

(TSXV:IMV)
Historical Stock Chart
From Jul 2023 to Jul 2024